New drug VV913 gets first safety check in healthy volunteers
NCT ID NCT07507838
First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This early-stage trial will test the safety and how the body handles a new drug called VV913. It involves 24 healthy Chinese men aged 18 to 45. Participants will receive either a low, medium, or high dose of VV913 or a placebo, and researchers will monitor side effects and drug levels in the blood. The goal is simply to gather safety information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VV913
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults